The Centers for Medicare and Medicaid Services published the Contract Year 2027 Medicare Advantage and Part D final rule on April 2, 2026. For specialty practices, the rule carries a direct message: payers will face significantly less regulatory oversight of their denial and utilization management behavior — and will receive $18.6 billion more in payments over the next decade in the process.
What CMS Changed
The final rule makes three consequential changes for specialty practice revenue cycles.
First, CMS removed 11 Star Ratings measures from the quality accountability framework. The eliminated measures focused on administrative processes and areas where plan performance showed low variation — including metrics tied to appeals and provider complaint tracking. These were the specific mechanisms that created accountability pressure on MA plans when denial patterns became systematic.
Second, CMS rolled back four health equity oversight requirements. Utilization management committees — the bodies that govern how MA plans approve or deny care — are no longer required to include a health equity expert or conduct annual health equity analyses of their denial decisions. MA quality improvement programs are no longer required to address health disparities. Plans are no longer required to send mid-year benefit utilization reminders to enrollees.
Third, CMS finalized a 2.48% rate increase for MA plans in 2027, translating to over $13 billion in additional MA payments to plans in CY 2027 alone. Plans receive more revenue while carrying fewer quality performance obligations.
The $18.6 Billion Figure
CMS estimates the Star Ratings changes will direct $18.6 billion in additional Medicare payments to MA insurers between 2027 and 2036 — equal to 0.21% of total Medicare payments to private plans over that period. That is $18.6 billion flowing to payers operating under a reduced set of quality accountability measures, with the appeals and complaint tracking mechanisms that held them accountable now removed.
The original proposed rule estimated this cost at $13.2 billion. The final figure is $5.4 billion higher than initially proposed.
What Was Removed and Why It Matters
The 11 removed Star Ratings measures included those tracking appeals outcomes and provider complaints against MA plans. For specialty practices, these were the data points that fed payer accountability. When an orthopedic group or ASC challenged a denial and won on appeal, that outcome was part of the Star Ratings record. That record influenced payer behavior.
With those measures gone, appeals wins no longer factor into plan quality scores. The financial and reputational incentive to avoid systematic denials is diminished.
The health equity rollbacks compound the issue. Utilization management committees — the internal bodies making prior authorization decisions — operated under requirements to examine whether their denial patterns created disparities. That requirement has been eliminated.
What This Means for Your Practice
Medicare Advantage plans already carry the highest denial burden for specialty practices. According to Kodiak Solutions’ 2025 industry report, MA final denial rates are more than double those of traditional Medicare. Clinical denial rates tied to prior authorization and medical necessity grew 14% for inpatient cases in 2024.
The CY 2027 final rule removes the regulatory mechanisms designed to create accountability for those patterns. For orthopedic, anesthesia, pain management, cardiology, and ASC practices — where MA enrollment represents a meaningful share of patient volume — fewer accountability measures means fewer constraints on payer denial behavior and more pressure on your revenue cycle to close the gap.
One narrow positive: CMS added a new Part C Depression Screening and Follow-Up measure, beginning with the 2027 measurement year. This is a meaningful signal for behavioral health access. It does not offset the broader deregulatory direction of the rule.
What This Means for Revenue Cycle Management
The rule does not change what your practice is entitled to be paid. It changes who is responsible for enforcing that entitlement. With fewer regulatory guardrails on payer behavior, the burden shifts to providers — and to the revenue cycle systems designed to fight back.
- Track every Medicare Advantage denial by payer, plan, and reason code — pattern recognition is now more important than ever
- File appeals within specialty-specific timelines — with appeals tracking removed from Star Ratings, payers have less incentive to reverse decisions voluntarily
- Audit prior authorization approval rates by MA plan for your specialty — baseline data is essential to identify where systematic denial patterns are emerging
- Evaluate MA contract participation — at least 19 health systems have dropped MA plans in 2026 citing denial rates; specialty practices should conduct their own MA profitability analysis
How Cosentus Helps
When regulatory guardrails are removed, your revenue cycle is the only mechanism left to protect your revenue from MA payer behavior. Cosentus provides:
- Medicare Advantage denial tracking and appeals management by payer and reason code
- Prior authorization workflows for high-denial specialties: orthopedics, pain management, anesthesia, and cardiology
- ASC-specific claim submission, denial follow-up, and underpayment identification
- Systematic appeals filing within specialty-appropriate timelines and payer-specific deadlines
Schedule your revenue cycle assessment → cosentus.com/contact
